Physician profile
Daniel S Oconnor
NPI 1437311800
$3,354.35
in general payments reported to CMS, 2019-2025
21 companies · $551 in 2025
The $551 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $694 · 2020: $227 · 2021: $462 · 2022: $383 · 2023: $726 · 2024: $312 · 2025: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,589.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,588.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $482.36 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $347.10 | 2020-2024 | |
| Heartflow, INC. | $306.30 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $289.58 | 2019-2025 | Farxiga, Lokelma |
| Abbott Laboratories | $255.32 | 2021 | |
| Janssen Pharmaceuticals, INC | $230.40 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $228.75 | 2022-2025 | Eliquis, Camzyos |
| Amgen INC. | $192.28 | 2021-2024 | Repatha |
| Medtronic Vascular, INC. | $190.77 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $190.61 | 2019 | |
| Medtronic, INC. | $142.15 | 2022 | |
| Novo Nordisk INC | $102.34 | 2025 | Ozempic, Wegovy |
| Bridgebio Pharma, INC. | $71.14 | 2025 | Attruby |
| Kiniksa Pharmaceuticals, Ltd. | $62.00 | 2022-2023 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $49.93 | 2025 | Amvuttra |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $49.44 | 2024-2025 | Nexletol |
| Lilly USA, LLC | $43.22 | 2025 | Mounjaro, Zepbound |
| Kiniksa Pharmaceuticals International, Plc | $42.83 | 2024 | Arcalyst |
| Pfizer INC. | $34.64 | 2025 | |
| Sanofi-Aventis U.S. LLC | $24.62 | 2021 | |
| Irhythm Technologies, INC. | $18.57 | 2023 | Zio Xt Patch |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Oconnor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.